Results 131 to 140 of about 69,107 (331)
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi +10 more
wiley +1 more source
Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients
Acta Dermato-VenereologicaDrug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes.
Dana Shalmon +7 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou +9 more
wiley +1 more source
Inflammatory Serine Proteases Play a Critical Role in the Early Pathogenesis of Diabetic Cardiomyopathy. [PDF]
, 2019 BACKGROUND/AIMS: Diabetic cardiomyopathy (DCM) is characterized by structural and functional alterations that can lead to heart failure. Several mechanisms are known to be involved in the pathogenesis of DCM, however, the molecular mechanism that links ...
Barbery, Carlos +9 more
core +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani +5 more
wiley +1 more source
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies [PDF]
, 2016 Ling Li +18 more
openalex +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee +15 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims To evaluate the glycaemic outcomes and safety of insulin glargine 300 U/mL (Gla‐300) in Chinese people with uncontrolled type 2 diabetes (T2D) by baseline age and disease duration. Materials and Methods INITIATION was a 24‐week, interventional, single‐arm study where adults with T2D (glycated haemoglobin [HbA1c] 7.5%–11.0%) received Gla ...
Liming Chen +12 more
wiley +1 more source